Novo Nordisk A/S
Rating
Updated: Aug 11, 2026Why Price Moved
Shares are trading higher after an EMA committee e...
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Novo Nordisk A/S is a global pharmaceutical firm dedicated to the investigation, creation, manufacturing, and distribution of medicinal products across a vast international footprint. Its market prese...
Latest News
5 hours ago · reuters.com
Novo says its next-gen obesity drug tops Lilly rival in late-stage studyNovo Nordisk said on Monday its next-generation experimental drug had achieved an estimated average weight loss of 12.4% in a late-stage trial and that it was superior to Eli Lilly's drug.
6 hours ago · reuters.com
Novo Nordisk aims to launch more than five blockbuster drugs by 2030, CEO saysNovo Nordisk aims to launch more than five blockbuster drugs by 2030 and to deliver more than 150 billion Danish crowns ($23 billion) in pipeline sales in 2035, its CEO Mike Doustdar said at its Capital Markets Day in London.
6 hours ago · wsj.com
Wegovy Maker Novo Nordisk Targets Several New Blockbuster Drugs in Coming YearsShares in Novo Nordisk fell more than 4% as its CEO laid out plans to launch new blockbuster drugs in the next few years while expanding into further treatment areas.
6 hours ago · wsj.com
Wegovy Maker Novo Nordisk Targets Several New Blockbuster Drugs in Coming Years — UpdateShares in Novo Nordisk fell more than 4% as its CEO laid out plans to launch new blockbuster drugs in the next few years while expanding into further treatment areas.
7 hours ago · marketwatch.com
Novo Nordisk stock tumbles as Ozempic maker sets out 2030 goalsNovo Nordisk stock tumbled on Monday as the weight-loss drug manufacturer failed to excite investors hoping for a turnaround.
7 hours ago · cnbc.com
Novo stock falls as much as 7% despite $23 billion sales target for blockbuster obesity drugsNovo stock falls as much as 7% despite $23 billion sales target for blockbuster obesity drugs
11 hours ago · reuters.com
Wegovy-maker Novo faces calls to map out strategy beyond weight-loss drugsWegovy-maker Novo Nordisk's CEO Mike Doustdar will face pressure on Monday to set out his strategy for competing with US rival Eli Lilly and how he plans to boost the company's growth beyond the blockbuster weight-loss drug.
2 days ago · benzinga.com
Congressman Ditches Magnificent Seven Stocks for Consumer Staples: Here's What He BoughtA member of Congress recently disclosed numerous stock trades, with some new names bought and some of the Magnificent Seven stocks sold. Here's a look at the trades and the Congress member's trading history.
2 days ago · zacks.com
Novo's Denecimig Gets CHMP Nod for Hemophilia A in the European UnionNVO's denecimig wins a positive European opinion for hemophilia A, with flexible dosing and a potential 2026 launch.
3 days ago · benzinga.com
EMA Committee Endorses Novo Nordisk's Hemophilia A TherapyNovo Nordisk A/S (NYSE:NVO) stock is trading higher on Thursday after the Danish drug maker achieved major advances across its therapeutic pipeline after securing a key European regulatory recommendation for its hemophilia A treatment and launching a major cardiometabolic research partnership.
Analyst Summary
Add to Watchlist
Select watchlists to add or remove NVO